Multimodality and Memory in the Mise en page of Guillaume de Machaut's Mass

Guillaume de Machaut’s mass survives in only five manuscripts, which all form part of the surprisingly homogeneous ‘complete works’ set of Machaut manuscripts. In this contribution, I argue that the details of mise en page in these manuscripts are reflective both of scribal memorial processes and multimodality in action: in this work where one of the major modes (image) is absent, the musical notation itself takes on an additional aesthetic role, that of visual beauty. In these manuscripts, the mass takes its place within the music section, surrounded there by lays, motets, virelais, and rondeaux, these surrounded (or preceded) by courtly ‘dits’ and lyrics not set to music. Four of these five manuscripts are illuminated, and all provide musical notation: all, therefore, are overtly multimodal. Despite the lavish illumination in the manuscripts, the mass is never adorned with a miniature, nor is it mentioned in Machaut’s ‘Prologue’ to his works. The aesthetic beauty of the mise en page of the mass, therefore, is derived from the musical notation, while the text-music setting shows a distinct divide between the two contrasting compositional techniques of the mass

HI absorption towards nearby compact radio sources

We present the results of HI absorption measurements towards a sample of nearby Compact Steep-Spectrum (CSS) and Giga-Hertz Peaked Spectrum (GPS) radio sources, the CORALZ sample, using the Giant Metrewave Radio Telescope (GMRT). We observed a sample of 18 sources and find 7 new detections. These sources are of lower luminosity than earlier studies of CSS and GPS objects and we investigate any dependence of HI absorption features on radio luminosity. Within the uncertainties, the detection rates and column densities are similar to the more luminous objects, with the GPS objects exhibiting a higher detection rate than for the CSS objects. The relative velocity of the blueshifted absorption features, which may be due to jet-cloud interactions, are within $\sim$$-$250 km s$^{-1}$ and do not appear to extend to values over 1000 km s$^{-1}$ seen for the more luminous objects. This could be due to the weaker jets in these objects, but requires confirmation from observations of a larger sample of sources. There appears to be no evidence of any dependence of HI column density on either luminosity or redshift, but these new detections are consistent with the inverse relation between HI column density and projected linear size.Comment: 10 pages, 6 figures, accepted for publication in MNRA

ISO observations of the interacting galaxy Markarian 297: with the powerful supernova remnant 1982aa

Markarian (Mkn) 297 is a complex system with two interacting galaxies. Observations were made with ISO using ISOCAM, ISOPHOT and LWS. We present ISOCAM maps at 6.7, 7.7, 12 and 14.3 microns which, with PHT-S spectrometry of the central interacting region, probe the dust obscured star formation and dust properties. ISOCAM reveals that the strongest emission region in the four MIR bands is completely unremarkable at visible and near-IR (e.g. 2MASS) wavelengths, and does not coincide with the nuclear region of either colliding galaxy. It shares this striking characteristic with the overlap region of the colliding galaxies in the Antennae (NGC 4038, 4039), the intragroup region of Stephan's Quintet, and IC 694 in the interacting system Arp 299. At 15 microns, the hidden source in Mkn 297 is, respectively, 14.6 and 3.8 times more luminous than the hidden sources in the Antennae (NGC 4038/4039) and Stephan's Quintet. Numerical simulations indicate that we see the Mkn 297 interaction about 1.5 x 10e8 years after the collision. ISOCAM shows knots and ridges of emission. The 14.3/7.7 micron ratio map implies widespread strong star formation. Strong emission features were detected in the ISOPHOT spectrum, while [OI], [OIII] and [CII] emission lines were seen with LWS. Using data from the three instruments, luminosities and masses for two dust components were determined. The total infrared luminosity is approximately 10e11 L_sol, marginally a LIRG. A 1979 supernova generated one of the most powerful known radio remnants (SN 1982aa) close to the strongest MIR source and identified with star forming region 14 in the optical. This exceptional supernova explosion may have been accompanied by a GRB, and a search for a GRB in this direction in contemporaneous satellite data is recommended.Comment: Accepted for publication in Astronomy and Astrophysics Updated to better use recent SN/GRB work and tune terminology in Sec. 4.

Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Dimethyl fumarate (DMF) inhibits inflammasome-mediated inflammation and has been proposed as a treatment for patients hospitalised with COVID-19. This randomised, controlled, open-label platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing multiple treatments in patients hospitalised for COVID-19 (NCT04381936, ISRCTN50189673). In this assessment of DMF performed at 27 UK hospitals, adults were randomly allocated (1:1) to either usual standard of care alone or usual standard of care plus DMF. The primary outcome was clinical status on day 5 measured on a seven-point ordinal scale. Secondary outcomes were time to sustained improvement in clinical status, time to discharge, day 5 peripheral blood oxygenation, day 5 C-reactive protein, and improvement in day 10 clinical status. Between 2 March 2021 and 18 November 2021, 713 patients were enroled in the DMF evaluation, of whom 356 were randomly allocated to receive usual care plus DMF, and 357 to usual care alone. 95% of patients received corticosteroids as part of routine care. There was no evidence of a beneficial effect of DMF on clinical status at day 5 (common odds ratio of unfavourable outcome 1.12; 95% CI 0.86-1.47; p = 0.40). There was no significant effect of DMF on any secondary outcome

Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Dimethyl fumarate (DMF) inhibits inflammasome-mediated inflammation and has been proposed as a treatment for patients hospitalised with COVID-19. This randomised, controlled, open-label platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing multiple treatments in patients hospitalised for COVID-19 (NCT04381936, ISRCTN50189673). In this assessment of DMF performed at 27 UK hospitals, adults were randomly allocated (1:1) to either usual standard of care alone or usual standard of care plus DMF. The primary outcome was clinical status on day 5 measured on a seven-point ordinal scale. Secondary outcomes were time to sustained improvement in clinical status, time to discharge, day 5 peripheral blood oxygenation, day 5 C-reactive protein, and improvement in day 10 clinical status. Between 2 March 2021 and 18 November 2021, 713 patients were enroled in the DMF evaluation, of whom 356 were randomly allocated to receive usual care plus DMF, and 357 to usual care alone. 95% of patients received corticosteroids as part of routine care. There was no evidence of a beneficial effect of DMF on clinical status at day 5 (common odds ratio of unfavourable outcome 1.12; 95% CI 0.86-1.47; p = 0.40). There was no significant effect of DMF on any secondary outcome